Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,202,270
  • Shares Outstanding, K 92,128
  • Annual Sales, $ 176,320 K
  • Annual Income, $ -189,290 K
  • 60-Month Beta 1.03
  • Price/Sales 6.83
  • Price/Cash Flow N/A
  • Price/Book 3.13
Trade FGEN with:

Options Overview

Details
  • Implied Volatility 75.05%
  • Historical Volatility 190.47%
  • IV Percentile 49%
  • IV Rank 24.41%
  • IV High 153.48% on 07/07/21
  • IV Low 49.73% on 08/24/20
  • Put/Call Vol Ratio 1.09
  • Today's Volume 265
  • Volume Avg (30-Day) 3,484
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 33,975
  • Open Int (30-Day) 56,406

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.48
  • Number of Estimates 8
  • High Estimate 0.80
  • Low Estimate -0.98
  • Prior Year -0.95
  • Growth Rate Est. (year over year) +49.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.54 +4.86%
on 07/27/21
27.88 -52.83%
on 06/29/21
-14.49 (-52.42%)
since 06/28/21
3-Month
12.54 +4.86%
on 07/27/21
30.12 -56.35%
on 06/25/21
-9.09 (-40.87%)
since 04/28/21
52-Week
12.54 +4.86%
on 07/27/21
57.21 -77.01%
on 02/12/21
-28.05 (-68.08%)
since 07/28/20

Most Recent Stories

More News
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III Platform

Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced...

FGEN : 13.17 (+0.92%)
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

AZN : 57.03 (-0.75%)
BIIB : 331.98 (-0.59%)
FGEN : 13.17 (+0.92%)
CTLT : 116.34 (+2.05%)
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an...

FGEN : 13.17 (+0.92%)
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging more than 20 years...

FGEN : 13.17 (+0.92%)
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee...

FGEN : 13.17 (+0.92%)
ALPMY : 17.3500 (+0.81%)
Thinking about buying stock in Pieris Pharmaceuticals, Paysafe, Tonix Pharmaceuticals, FibroGen, or Arbutus Biopharma?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, PSFE, TNXP, FGEN, and ABUS.

ABUS : 2.73 (+1.11%)
FGEN : 13.17 (+0.92%)
TNXP : 0.7265 (-0.48%)
PIRS : 3.44 (+2.69%)
PSFE : 10.58 (+0.95%)
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

-- FibroGen Exclusively Licenses HiFiBiO's Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs

FGEN : 13.17 (+0.92%)
Pancreatic Cancer Action Network Partners With FibroGen To Bring New Experimental Treatment Arm To Adaptive Clinical Trial, Precision Promise(SM)

/PRNewswire/ -- The  (PanCAN), a leading pancreatic cancer advocacy organization, announced today the latest update to its novel clinical trial platform, , with the addition of a new treatment arm by...

FGEN : 13.17 (+0.92%)
Pamrevlumab Included in Pancreatic Cancer Action Network's Adaptive Clinical Trial Platform

FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise adaptive trial platform evaluating pamrevlumab [and standard...

FGEN : 13.17 (+0.92%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United...

FGEN : 13.17 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 14.06
2nd Resistance Point 13.66
1st Resistance Point 13.35
Last Price 13.17
1st Support Level 12.64
2nd Support Level 12.24
3rd Support Level 11.93

See More

52-Week High 57.21
Fibonacci 61.8% 40.15
Fibonacci 50% 34.87
Fibonacci 38.2% 29.60
Last Price 13.17
52-Week Low 12.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar